deltatrials
Recruiting PHASE1 INTERVENTIONAL 1-arm NCT06880081

Study of PN20 in Adult Patients With Primary Immune Thrombocytopenia (ITP)

A Phase 1b, Open-label, Single-arm, Dose-escalation Study of PN20 in Patients With Primary Immune Thrombocytopenia (ITP)

Sponsor: Chongqing Peg-Bio Biopharm Co., Ltd.

Conditions Primary Immune Thrombocytopenia (ITP)
Interventions PN20 treatment
Updated 2 times since 2025 Last updated: Feb 26, 2026 Started: Mar 7, 2025 Primary completion: Feb 27, 2026 Completion: Apr 28, 2026
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Primary Immune Thrombocytopenia (ITP), this trial is actively recruiting participants. The trial is conducted by Chongqing Peg-Bio Biopharm Co., Ltd. and has accumulated 2 data snapshots since 2025. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Apr 2025 – ~Mar 2026 · 11 months · monthly snapshotRecruiting~Mar 2026 – present · 5 months · monthly snapshotRecruiting

Change History

2 versions recorded

  1. Mar 2026 — Present [monthly]

    Recruiting PHASE1

  2. Apr 2025 — Mar 2026 [monthly]

    Recruiting PHASE1

    First recorded

Mar 2025

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Chongqing Peg-Bio Biopharm Co., Ltd.
Data source: Chongqing Peg-Bio Biopharm Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations